Zhejiang East-Asia Pharmaceutical (605177.SH): The raw material drug Lu Likang received the South Korean raw material drug registration certificate.

15:34 20/01/2025

East Asia Pharmaceutical (605177.SH) issued an announcement that they recently received approval from the South Korean Food and Drug Administration (Korea...

Zhejiang East-Asia Pharmaceutical (605177.SH) announced that recently, the company has received the raw material drug registration certificate from the South Korean Ministry of Food and Drug Safety (Korean MFDS) for the product named Voriconazole. Voriconazole is used to treat skin superficial fungal infections caused by sensitive fungi, such as athlete's foot, body ringworm, jock itch, and can also be used for cutaneous candidiasis and tinea versicolor. The receipt of the Voriconazole raw material drug registration certificate in South Korea marks the company's eligibility for market access in South Korea. This will have a positive impact on expanding the company's presence in the South Korean pharmaceutical market, thus promoting the sales of Voriconazole raw material drugs in other overseas markets.

HXTL (01085) issued a profit warning, expecting an unaudited net loss of approximately 41 million to 43 million yuan for the year, compared to a profit year-on-year.

WEIYE HOLDINGS (01570) released its performance for the year 2025, with a net loss attributable to shareholders of 452 million yuan, an increase of 45.3% year-on-year.

Shanghai Fudan (01385) released its annual performance, with a net profit attributable to the parent company of 232 million yuan, a year-on-year decrease of 59.42%.

HXTL (01085) issued a profit warning, expecting an unaudited net loss of approximately 41 million to 43 million yuan for the year, compared to a profit year-on-year.

WEIYE HOLDINGS (01570) released its performance for the year 2025, with a net loss attributable to shareholders of 452 million yuan, an increase of 45.3% year-on-year.

Shanghai Fudan (01385) released its annual performance, with a net profit attributable to the parent company of 232 million yuan, a year-on-year decrease of 59.42%.